TNF Pharmaceuticals, Inc. Common Stock (TNFA)

• Market cap: $3.31M
• 1 day: -2.44%
• 5 days: -13.04%
• 1 month: -33.33%
• 3 months: -33.70%
• 6 months: -42.86%
• Year to date: -84.00%
• 1 year: -88.57%
• 5 years: -99.11%
• 10 years: -99.11%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

Employees: 6

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

1.57% more ownership

Funds ownership: 0% [Q2] → 1.57% (+1.57%) [Q3]

17% less funds holding

Funds holding: 23 [Q2] → 19 (-4) [Q3]

48% less capital invested

Capital invested by funds: $115K [Q2] → $60.1K (-$54.9K) [Q3]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7